The peptide space has a new obsession. And I get it — when you hear "24% body fat loss in a clinical trial," your brain does exactly what it's supposed to do. It locks in.

That drug is retatrutide. And yeah, the numbers are real.

But here's what most people aren't talking about — and what I think matters a lot more than which drug sounds most impressive on paper.

What These Drugs Actually Are

Both tirzepatide and retatrutide are injectable drugs that work by mimicking hormones your gut already produces. These hormones signal to your brain that you're full, slow down how fast your stomach empties, and help regulate blood sugar. The result is that people eat less, feel less driven by hunger, and lose a significant amount of body weight over time.

Tirzepatide hits two of these hormone receptors — GIP and GLP-1. That dual action is already a meaningful upgrade over the early GLP-1 drugs like semaglutide. Clinical trials showed average weight loss in the range of 20 to 22 percent of body weight. That's not a modest effect. That's life-changing for a lot of people.

Retatrutide goes one step further. It hits three receptors — GIP, GLP-1, and glucagon. That third receptor, the glucagon one, is where things get interesting. Glucagon typically raises blood sugar, but when you activate it in combination with the other two, it increases how much energy your body burns at rest. You're not just eating less. You're burning more. That's the mechanism behind the higher numbers — up to 24 percent body weight reduction in Phase 2 trials.

Who's Actually Using These

Tirzepatide is FDA approved. That means it's accessible right now through a doctor, through telehealth, and through compounding pharmacies (though that landscape is changing fast — worth staying updated). The people using it are everywhere from metabolic clinics to your neighbor who lost 60 pounds last year and looks like a different person.

The user profile tends to be people dealing with obesity, type 2 diabetes, or metabolic dysfunction who need a significant intervention. Not people trying to drop the last 15 pounds for aesthetics. Not athletes optimizing performance. People whose metabolic health is genuinely impaired and who haven't found traction with conventional approaches.

Retatrutide is still in Phase 3 trials. It is not available through a doctor. If someone is telling you they have retatrutide, that's a research chemical situation — not a pharmaceutical one. The community talks about it constantly because the numbers are exciting, but it's not a clinical option yet.

Why Everyone Gravitates Toward Retatrutide

Because 24 percent sounds better than 20 percent. That's literally it. Human brains love a bigger number.

The glucagon component feels like the secret sauce. And in terms of mechanism, it is genuinely interesting. The idea that you can increase metabolic rate while suppressing appetite at the same time is a real pharmacological advantage.

But here's what the trials don't tell you in the headline: that glucagon activation also introduces more complexity around side effects. The GI effects — nausea, vomiting, diarrhea — are common across this whole class of drugs. The glucagon piece adds additional questions around lean mass preservation that are still being studied. The highest doses in the Phase 2 trial also came with the highest dropout rates. Bigger numbers, bigger tradeoffs.

Why Tirzepatide Might Actually Be the Smarter Starting Point

Here's what the retatrutide hype glosses over. That third receptor is also the reason people at higher doses had a rougher time. More nausea, more GI distress, higher dropout rates. When you're pushing three hormonal systems at once, your body feels it.

Tirzepatide is more tolerable. The side effect profile is softer, most people adjust within the first few weeks of titration, and they find a dose they can actually stay on without fighting the drug every injection.

That last part matters more than any trial number. The best drug is the one you can stick with. A 20 percent weight loss you maintain for 18 months beats a 24 percent loss you abandoned at month four because the side effects became unmanageable.

If you're someone who is sensitive to medications, has a history of GI issues, or just wants a more predictable experience while still getting serious results, tirzepatide is the more forgiving option. It's not the consolation prize. It's the smarter entry point for most people.

Where These Fit in the Bigger Picture

Neither of these is a peptide in the way your community probably thinks about peptides. They don't touch the growth hormone axis. They don't support tissue repair, recovery, or cellular regeneration the way BPC-157, TB-500, or the GHRH/GHRP stack does. They're working on a completely different lever — gut hormone signaling and appetite regulation.

For someone optimizing performance, sleep, recovery, and longevity, incretin drugs are not in the same conversation as BPC or Ipamorelin or Semax. They solve a different problem.

For someone with serious metabolic dysfunction who needs a major intervention before they can even begin an optimization protocol — these drugs can be the thing that changes everything.

Personally I like to microdose both tirzepatide and retatrutide 500mcg’s three times a week, Monday, Wednesday, Friday. Splitting the dose across the week instead of one larger weekly injection keeps blood levels more stable and tends to be easier on the gut. For people who are leaner and more metabolically healthy, this approach is usually the sweet spot.

For someone with more significant metabolic dysfunction, higher doses make sense. The 1.5mg range and beyond is where the more aggressive intervention begins and that population typically needs that level of input to move the needle.

The question is always: which tool does this person actually need?

BEFORE YOU PIN ANYTHING

One thing that trips people up once tirzepatide is actually in their hands is reconstitution. Most people have never done it before and the last thing you want is to mess up a vial because you guessed on the process. I broke the whole thing down step by step in my latest Rumble video. How much BAC water to use, how to draw it properly, how to store it after. Everything you need before your first injection. Go watch it before you do anything else.

Watch here 👇

OFFICIALLY A 1ST PHORM ATHLETE

If you're running one of these protocols and your nutrition isn't dialed in, the results are going to be half of what they could be. I recently partnered with 1st Phorm and I only bring on brands I actually stand behind. They make clean, no-nonsense supplements that fit the kind of lifestyle this community is built around. Protein, creatine, hydration, greens — the basics done right.

Shop Below 👇

Stay curious,

Lee

P.S. — If your community members are already on tirzepatide and asking about what to stack with it, that's a deep dive worth doing inside the community.

Peptide Discounts and Deals

Follow me on Social Media

Studies:

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes. The Lancet, 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext

  3. Jastreboff AM, et al. Triple Hormone Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

  4. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519

  5. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetologia, 2021. https://link.springer.com/article/10.1007/s00125-021-05361-8

Keep Reading